Jon Halbert - 15 May 2026 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)

Reporting relationship: Director
Issuer ticker: CAI
Reported as of: 15 May 2026
Net transaction value: +$990,080
SEC form: 4
Accepted by SEC: 13 Jul 2026, 07:06:08 UTC
Prior SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

Jon Halbert filed Form 4 for Caris Life Sciences, Inc. (CAI) on 13 Jul 2026.

Key facts

This page summarizes Jon Halbert's Form 4 filing for Caris Life Sciences, Inc. (CAI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Jul 2026, 07:06.

Change

Previous filing in this sequence was filed on 27 Feb 2026.
Current net transaction value: +$990,080.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001189394 Primary reporting owner

HALBERT JON

Relationship: Director
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Purchase

Transaction value: $990,080
Shares: +68,000
Change %: +11%
Price: $14.56
Shares after: 704,598
Date: 15 May 2026
Ownership: By LAH Investments, Ltd.
Footnotes: F2, F3, F4

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 118,621
Date: 15 May 2026
Ownership: Direct

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 637,887
Date: 15 May 2026
Ownership: By Family Trust
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes an aggregate of 23,196 shares received in pro rata distributions exempt pursuant to Rule 16a-9.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F3

Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9.

Footnote F4

The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.